Is Risperidone Less Sedating Than Olanzapine?
Yes, risperidone is generally less sedating than olanzapine, though both medications can cause sedation as a common adverse effect.
Evidence from Guidelines and Drug Labels
The most direct evidence comes from the 2018 ESMO delirium guidelines 1, which explicitly list olanzapine as causing drowsiness in their pharmacological intervention table, while risperidone is noted to potentially cause drowsiness but also insomnia, agitation, and anxiety—suggesting a less consistently sedating profile. The guidelines describe olanzapine as having sedating properties, whereas risperidone's side effect profile is more mixed.
The FDA drug label for risperidone 2 confirms that sedation occurs but lists multiple activating symptoms (insomnia, agitation, anxiety, akathisia) alongside drowsiness, indicating a more variable sedation profile compared to olanzapine's more consistent sedating effects.
Comparative Clinical Evidence
Direct Comparison Studies
A 2005 randomized controlled trial in healthy volunteers 3 demonstrated that olanzapine subjects experienced significantly more sedation versus placebo, while risperidone subjects also had sedation but the study design showed olanzapine's sedating effects were more pronounced in the context of weight gain and metabolic changes.
A 2015 delirium management study 4 found that sedation occurred most frequently with olanzapine (28.6%) compared to other antipsychotics including risperidone (where extrapyramidal symptoms were more common at 4.8% rather than sedation being the primary concern).
Youth Population Data
The 2016 SATIETY study 5 in antipsychotic-naïve youth showed that aripiprazole had lower rates of sedation, while olanzapine showed lower rates of activation. Importantly, the study found that drowsiness prevalence was 85% across all four SGAs studied (including both risperidone and olanzapine), but the compound measure SEDATION+ showed lower rates with aripiprazole (p=0.018), with olanzapine trending toward more sedation.
Meta-Analysis Findings
The 2006 Cochrane review 6 comparing risperidone versus olanzapine found that about 30% of patients experienced sleepiness with both drugs (n=1713,6 RCTs, RR 0.92 CI 0.79 to 1.07), showing no statistical difference. However, the clinical context matters: olanzapine's sedation was associated with higher weight gain and metabolic effects, while risperidone's side effect profile leaned more toward extrapyramidal symptoms.
Clinical Algorithm for Selection
When sedation is a primary concern:
Choose risperidone over olanzapine if the patient:
- Needs to maintain daytime alertness and functioning
- Has a history of excessive sedation with other medications
- Is at risk for metabolic syndrome (as olanzapine's sedation often accompanies significant weight gain)
Consider olanzapine over risperidone if the patient:
- Has severe insomnia or agitation requiring sedation
- Cannot tolerate extrapyramidal symptoms (risperidone causes more EPS)
- Needs nighttime sedation as a therapeutic benefit
Dosing considerations:
- Risperidone: Start 0.5-1 mg; sedation may occur but is less predictable
- Olanzapine: Start 2.5-5 mg at bedtime; expect sedation as a consistent effect 1
Important Caveats
Both medications commonly cause sedation—the 2004 review 7 notes that while atypical antipsychotics "generally cause less sedation" than conventional antipsychotics, sedation remains a significant issue with both risperidone and olanzapine. The difference is one of degree and consistency, not absolute presence or absence.
Individual variation is substantial: The 2015 youth study 5 found that clinical parameters (age, baseline functioning, diagnosis) predicted sedation more strongly than specific medication choice, though medication differences were still statistically significant.
Combination with benzodiazepines: The ESMO guidelines 1 specifically warn about combining olanzapine with benzodiazepines due to risk of oversedation and respiratory depression—a caution not as prominently noted for risperidone.